HCC
Clinical trials for HCC explained in plain language.
Never miss a new study
Get alerted when new HCC trials appear
Sign up with your email to follow new studies for HCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to shrink untreatable liver tumors
Disease control OngoingThis phase II trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a radiation procedure called Y-90 SIRT can shrink liver tumors in people with intermediate-stage liver cancer that cannot be removed by surgery. About 55 participants will recei…
Matched conditions: HCC
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Epigenetic drug may re-sensitize liver tumors to immunotherapy
Disease control OngoingThis phase 2 trial investigates whether adding an epigenetic drug (CXD101) to an immunotherapy (Geptanolimab) can help patients with advanced liver cancer whose disease has stopped responding to prior checkpoint inhibitors. The study enrolls about 26 adults with hepatocellular ca…
Matched conditions: HCC
Phase: PHASE2 • Sponsor: Stephen Chan Lam • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental CAR-T therapy takes on Hard-to-Treat liver cancer
Disease control OngoingThis early-phase trial tests a new type of immune cell therapy called IL1RAP-targeting CAR-T cells in just 3 people with advanced liver cancer that has not responded to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Resea…
Matched conditions: HCC
Phase: PHASE1 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Custom-Made DNA vaccine takes on advanced liver cancer
Disease control OngoingThis study tests a personalized DNA vaccine (GNOS-PV02) combined with an immune booster and the immunotherapy drug pembrolizumab in 36 adults with advanced hepatocellular carcinoma (HCC). The vaccine is custom-made for each patient based on their tumor's unique genetic markers. T…
Matched conditions: HCC
Phase: PHASE1, PHASE2 • Sponsor: Geneos Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could an immunotherapy drug tame liver cancer in hepatitis b patients?
Disease control OngoingThis phase 2 trial is testing the drug pembrolizumab in 30 people with advanced liver cancer linked to hepatitis B. Participants receive pembrolizumab every 3 weeks, and researchers will check how the tumors respond and how the immune system changes. The goal is to see if this im…
Matched conditions: HCC
Phase: PHASE2 • Sponsor: CCTU • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for liver cancer patients who stop responding to immunotherapy?
Disease control OngoingThis phase II trial tests the drug cabozantinib in 20 people with advanced liver cancer (HCC) whose disease got worse after immunotherapy. The goal is to see if cabozantinib can slow tumor growth and improve survival. It is a small, early study, so results are not yet conclusive.
Matched conditions: HCC
Phase: PHASE2 • Sponsor: Stephen Chan Lam • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for advanced liver cancer: experimental drug takes on standard therapy
Disease control OngoingThis study compares a new drug, pracytarabine, to the standard drug regorafenib in 60 people with advanced liver cancer that has stopped responding to targeted therapy and immunotherapy. The goal is to see if pracytarabine can help patients live longer. Participants receive eithe…
Matched conditions: HCC
Phase: PHASE2, PHASE3 • Sponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC